Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 06 Mar 2023
USA: The syrup drug Diethylene glycol (DEG), a drug commonly used to prevent infections, is the cause of kidney disease...
Read Full NewsAccurate and Timely Diagnosis of Endometriosis
Bridging Specialties to Manage Hyperglycemia in Breast Cancer Patients Treated With PI3K/AKT Pathway Inhibitors
Recognizing the Multifactorial Barriers to Effective Weight Loss in Obesity
From Crisis to Control: Strategies to Address Recurrent Severe Hypoglycemia in Type 1 Diabetes
Contraceptive Considerations in the Modern Era: Navigating Non-Oral Options and Evolving Clinical Complexities
"It really pays to be very, very, very skeptical," says one expert
Experts call for better guidance on levothyroxine initiation, deprescribing
1.
How a new light-based cancer treatment could destroy tumors without harming healthy cells—using LEDs
2.
Second Malignancy Risk With CAR T-Cell Therapy on Par With Other Treatments
3.
Waist circumference outshines BMI as obesity-related cancer risk marker in men, but not women
4.
Telehealth in the pandemic era resulted in fewer therapy interruptions.
5.
Citing a cancer risk, the EPA sets a new limit on medical sterilization chemicals.
1.
Organoids & Single-Cell Tools: Breakthroughs in Colorectal Cancer Research
2.
AI-Powered Rehabilitation: A Game Changer for Hemophilia Management
3.
Artificial Intelligence in Oncology: Current Trends, Challenges and Future Outlook
4.
From Bench to Bedside: The New Era of Lymphoma Treatment and Education
5.
Uncovering the Hidden Gallons: How Much Blood Is Inside the Human Body?
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients
2.
Navigating the Complexities of Ph Negative ALL - Part VIII
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge